

Title (en)  
PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING TH1 AND TH2 CELL RELATED DISEASES BY MODULATING THE TH1/TH2 RATIO.

Title (de)  
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR PROPHYLAXE ODER BEHANDLUNG VON TH1- UND TH2-ZELLE VERWANDTEN ERKRANKUNGEN, DURCH MODULIERUNG DES TH1/TH2 VERHÄLTNISSES

Title (fr)  
COMPOSITIONS PHARMACEUTIQUES DESTINES A PREVENIR OU TRAITER LES MALADIES ASSOCIEES AUX CELLULES TH1 ET TH2 PAR MODULATION DU RAPPORT TH1/TH2

Publication  
**EP 1418936 A2 20040519 (EN)**

Application  
**EP 02724144 A 20020507**

Priority  
• DK 0200295 W 20020507  
• DK PA200100726 A 20010509  
• US 28971101 P 20010509

Abstract (en)  
[origin: WO02089832A2] Pharmaceutical composition for preventing or treating a Th1 cell- or Th2-cell-related disease in a human or an animal by modulating the Th1/Th2 ratio comprising an active substance consisting of (i) IL-4 and SDF-1 alpha , or IL-2 and SDF-1 alpha , respectively, as well as modulators thereof, (ii) an IL-4 stimulating adjuvant and SDF-1 alpha , or an IL-2 stimulating adjuvant and SDF-1 alpha , respectively, (iii) a modulator of the tyrosine kinases Syk or ZAP-70, or (iv) a modulator of the nuclear factors of activated T cells NFAT1 or NFAT2.

IPC 1-7  
**A61K 38/20**; **A61K 39/395**; **A61K 31/7125**; **A61K 38/45**; **A61K 38/17**; **A61K 31/00**; **C12N 15/11**; **C12Q 1/68**; **G01N 33/50**; **C12N 5/00**; **A61P 37/00**; **A61P 35/00**

IPC 8 full level  
**A61K 31/00** (2006.01); **A61K 31/7088** (2006.01); **A61K 31/7125** (2006.01); **A61K 33/06** (2006.01); **A61K 33/24** (2019.01); **A61K 33/40** (2006.01); **A61K 33/42** (2006.01); **A61K 38/00** (2006.01); **A61K 38/17** (2006.01); **A61K 38/19** (2006.01); **A61K 38/20** (2006.01); **A61K 39/35** (2006.01); **A61K 39/39** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 48/00** (2006.01); **A61P 31/04** (2006.01); **A61P 35/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/06** (2006.01); **A61P 43/00** (2006.01); **C12N 5/0783** (2010.01); **C12Q 1/48** (2006.01); **G01N 33/50** (2006.01)

CPC (source: EP US)  
**A61K 31/00** (2013.01 - EP); **A61K 31/7125** (2013.01 - EP); **A61K 33/06** (2013.01 - EP); **A61K 33/24** (2013.01 - EP US); **A61K 33/42** (2013.01 - EP); **A61K 38/1709** (2013.01 - EP); **A61K 38/1793** (2013.01 - EP); **A61K 38/195** (2013.01 - EP); **A61K 38/2013** (2013.01 - EP); **A61K 38/2026** (2013.01 - EP); **A61K 38/45** (2013.01 - EP); **A61K 39/39** (2013.01 - EP); **A61P 31/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C12N 5/0636** (2013.01 - EP US); **C12Q 1/485** (2013.01 - EP); **G01N 33/505** (2013.01 - EP); **A61K 2039/5158** (2013.01 - EP US); **A61K 2039/55516** (2013.01 - EP); **A61K 2039/55527** (2013.01 - EP); **A61K 2039/55533** (2013.01 - EP); **A61K 2039/57** (2013.01 - EP); **C12N 2501/23** (2013.01 - EP)

C-Set (source: EP)  
1. **A61K 31/7125 + A61K 2300/00**  
2. **A61K 33/24 + A61K 2300/00**  
3. **A61K 38/1709 + A61K 2300/00**  
4. **A61K 38/19 + A61K 2300/00**  
5. **A61K 38/2013 + A61K 2300/00**  
6. **A61K 38/2026 + A61K 2300/00**

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 02089832 A2 20021114**; **WO 02089832 A3 20040325**; CA 2447360 A1 20021114; CN 1531440 A 20040922; EP 1418936 A2 20040519; JP 2004536800 A 20041209

DOCDB simple family (application)  
**DK 0200295 W 20020507**; CA 2447360 A 20020507; CN 02813325 A 20020507; EP 02724144 A 20020507; JP 2002586964 A 20020507